腎移植患者
腎移植後の患者20
腎移植を受けた18歳以上の成人を対象に、組換え帯状疱疹ワクチン(RZV)を1~2ヶ月間隔で2回筋肉内投与し、安全性と免疫原性を評価した第Ⅲ相無作為化観察者盲検プラセボ対照多施設共同試験。20,29-31
試験デザイン20,31
*The second dose of vaccine/placebo will be administered 1 to 2 months after the first dose.
†Month 2 (Visit 3), Month 7 (Visit 4) and Month 13 (Visit 5) occurred within 1, 6 and 12 months of the second vaccination, respectively. RZV, recombinant zoster vaccine; YOA, years of age.
年齢層別の液性免疫応答率20
Humoral response was measured at Mo 2, Mo 7 and Mo 13, which occurred within 1, 6 and 12 months of the second vaccination, respectively.
Mo, month; RZV, recombinant zoster vaccine; VRR, vaccine response rate; YOA, years of age.
Reproduced from Vink P et al. 2020 under the terms of a Creative Commons CC-BY licence (http://creativecommons.org/licenses/by/4.0/).
年齢層別の細胞性免疫応答率20
Cell-mediated immune response was measured at Mo 2 and Mo 13, which occurred within 1 and 12 months of the second vaccination, respectively.
CMI, cell-mediated immunity; Mo, month; RZV, recombinant zoster vaccine; VRR, vaccine response rate; YOA, years of age
Reproduced from Vink P et al. 2020 under the terms of a Creative Commons CC-BY licence (http://creativecommons.org/licenses/by/4.0/).
RZVワクチン接種後の液性免疫応答率は、2回目接種1ヶ月後で80.2%、13ヶ月後で66.7%であった。各時点で、液性免疫応答および細胞性免疫応答は、18-49 歳の若年層で 50 歳以上の層よりも高かった。
年齢に関係なく、腎移植後 4~18ヶ月にワクチン投与された場合、gEに対する液性および細胞性免疫応答が誘導された20
Grade 3 pain defined as significant pain at rest and preventing normal activity; grade 3 redness and swelling defined as surface diameter >100 mm. Fever defined as ≥37.5°C; Fever was not graded in this study. Fever >39.0°C presented as grade 3.
For all others, grade 3 AEs defined as preventing normal activity.
AE, adverse event; GI, gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain); RZV, recombinant zoster vaccine.
Graphs reproduced from Vink P et al. 2020 under the terms of a Creative Commons CC-BY licence (http://creativecommons.org/licenses/by/4.0/), with additional data from ClinicalTrials.gov. NCT02058589.
最も一般的な局所および全身性の特定有害事象は、注射部位疼痛、疲労、筋肉痛でした。9 発現した有害事象は主に軽度から中等度であり、一過性のものでした。全体として、副反応は許容できるものであり、患者の状態から予想されるものでした。20
AE, adverse event; pIMD, potential immune-mediated disease; RZV, recombinant zoster vaccine; SAE, serious adverse event.
The graph has been independently created by GSK from Vink P, et al. Clin Infect Dis. 2020;70(2):181–190.
RZV 群とプラセボ群との間で、AE、SAE(死亡に至るSAE含む)、免疫の関与が疑われる疾患(pIMD)、生検で証明された拒絶反応、移植臓器の機能変化について、明らかな差は認められませんでした20
Abbreviations
AE, adverse event; ART, anti-retroviral therapy; ATP, according to protocol; BCL, B-cell lymphoma; CLL, chronic lymphocytic leukaemia; CMI, cell-mediated immunity; gE, glycoprotein E; GI, gastrointestinal; GMC, geometric mean concentration; HIV, human immunodeficiency virus; IQR, interquartile range; LL, lower limit; Mo, month; mTVC, modified total vaccinated cohort; pIMD, potential immune-mediated disease; PHN, post-herpetic neuralgia; Pre, pre-vaccination; Q, quartile; RZV, recombinat zoster vaccine; SAE, serious adverse event; TVC, total vaccinated cohort; UL, upper limit; VE, vaccine efficacy; VRR, vaccine response rate; YOA, years of age
References
- Chen SY, et al. Infection. 2014;42(2):325–334
- Zhang D, et al. Adv Ther. 2017;34(7):1610–1621.
- Sahoo F, et al. Biol Blood Marrow Transplant. 2017;23(3):505–511.
- Winston DJ, et al. Lancet. 2018;391(10135):2116–2127
- Bastidas A, et al. JAMA. 2019;322(2):123–133
- Habel LA, et al. Cancer Epidemiol Biomarkers Prev. 2013;22(1):82–90
- Dagnew AF, et al. Lancet Infect Dis. 2019;19(9):988–1000
- Koo S, et al. Transpl Infect Dis. 2014;16(1):17–25
- Pergam SA, et al. Transpl Infect Dis. 2011;13(1):15–23
- Arness T, et al. Transpl Infect Dis. 2008;10(4):260–268
- Mao J, et al. Medicine (Baltimore). 2017;96(48):e8746
- Tseng HF, et al. Clin Infect Dis. 2014;59(7):913–919
- Blank LJ, et al. J Acquir Immune Defic Syndr. 2012;61(2):203–207
- Chakravarty EF. Rheum Dis Clin North Am. 2017;43(1):111–121
- Veetil BM, et al. Arthritis Care Res (Hoboken). 2013;65(6):854–861
- Khan N, et al. Clin Gastroenterol Hepatol. 2018;16(12):1919–1927
- Johnson BH, et al. BMC Infect Dis. 2015;15:502
- Dagnew AF, et al. Hum Vaccin Immunother. 2021;17(11):4132–4143
- Berkowitz EM, et al. J Infect Dis. 2015;211(8):1279–1287
- Vink P, et al. Clin Infect Dis. 2020;70(2):181–190
- Vink P, et al. Cancer. 2019;125(8):1301–1312
- de la Serna J, et al. Efficacy and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients 18 Years of Age or Older: First Results of the Phase 3 Randomized, Placebo-Controlled ZOE-HSCT Clinical Trial. Presented at BMT Tandem Meeting; 25th February 2018; Salt Lake City, UT, USA.
- ClinicalTrials.gov. NCT01610414. Available at: https://clinicaltrials.gov/ct2/show/study/NCT01610414 (accessed May 2023).
- Zoster-002 Clinical Study Report 115523. Available at: https://www.gsk-studyregister.com/study/4539 (accessed May 2023).
- Zoster-039 Clinical Study Report 116428. Available at: https://www.gsk-studyregister.com/en/trial-details/?id=116428 (accessed May 2023)
- ClinicalTrials.gov. NCT01798056. Available at: https://clinicaltrials.gov/ct2/show/NCT01798056 (accessed May 2023).
- Zoster-028 Clinical Study Report 116427. Available at: https://gsk-clinicalstudyregister.com/files2/116427-Clinical-Study-Result-Summary.pdf (accessed May 2023).
- Vink P. Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical Trial. Poster #1349. Presented at IDWeek; 4–8 October, 2017; San Diego, CA, USA.
- ClinicalTrials.gov. NCT02058589. Available at: https://clinicaltrials.gov/ct2/show/NCT02058589 (accessed May 2023).
- Vink P, et al. Open Forum Infect Dis. 2018;5(suppl 1):S744–S745
- Zoster-041 Clinical Study Report 116886. Available at: https://www.gsk-studyregister.com/en/trial-details/?id=116886 (accessed May 2023).
- Zoster-015 Clinical Study Report 112673. Available at: https://gsk-clinicalstudyregister.com/files2/gsk-112673-clinical-study-report-redact.pdf (accessed May 2023).
NX-JP-SGX-WCNT-230014 | December 2023